SMARCA4 and neoplasm: In summary, the SMARCA4-deficient tumors with a KRAS oncogenic activation are associated with a better prognosis, as the tumor will be less progressive, low grade, and with lower tumor burden as compared to a SMARCA4 intact KRAS co-mutated NSCLC.